Tag: Vaccine
Bharat Biotech celebrates 3 decades of scientific excellence and global vaccine...
Over the past 30 years, Bharat Biotech has grown from a single facility in Hyderabad into a global vaccine powerhouse
Novo Medi Sciences launches NEXIPOX PLUS, a next-generation Varicella vaccine built...
The vaccine has demonstrated a favourable safety profile in clinical studies with no serious adverse events causally linked to it in comparative clinical trials
Indian Immunologicals clarifies on Abhayrab vaccine, counters misplaced advisory reference
In a statement, IIL issued a clarification regarding the alert issued by the Australian Technical Advisory Group on the circulation of counterfeit batches of vaccine since November 2023
Biofabri, Bharat Biotech sign tech transfer deal for TB vaccine MTBVAC
MTBVAC represents a critically important advance in global TB prevention, as it’s one of two vaccine candidates that have progressed into advanced clinical development.
WHO prequalifies Shantha Biotech’s ‘Shanchol’ Oral Cholera Vaccine to ensure global...
This milestone enables global procurement agencies such as UNICEF, Gavi, and PAHO to source Shanchol® for use in countries where cholera remains a major public health challenge
Indian Immunologicals unveils India’s first gE-deleted DIVA marker vaccine for IBR
Millions of livestock and farmers are expected to be benefited from this vaccine
Vidal Health and Serum Institute of India collaborate on HPV Vaccine...
First-of-its-kind digital health programme on Vidal Health’s platform will offer an end- to-end, convenient and cashless experience, making HPV vaccine more accessible
Premas Biotech wins Gates Foundation grant to advance thermostable rabies vaccine
Funding to support early-stage development of innovative rabies vaccine for low- and middle-income countries
Indian Immunologicals pledges 5 lakh doses of veterinary anti-rabies vaccine for...
The world's largest manufacturer of rabies vaccines launches massive CSR drive to strengthen India’s One Health Mission
Pfizer launches PCV20 in India to protect adults against pneumococcal disease
Approved for use in adults 18 years of age and older, Pfizer’s vaccine protects against more serotypes of pneumococcal disease than any other conjugate vaccine previously available in India